Home » Stocks » NBTX

Nanobiotix S.A. (NBTX)

Stock Price: $15.65 USD -0.43 (-2.66%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 538.78M
Revenue (ttm) 3.06M
Net Income (ttm) -40.96M
Shares Out 34.43M
EPS (ttm) -1.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $15.65
Previous Close $16.08
Change ($) -0.43
Change (%) -2.66%
Day's Open 15.96
Day's Range 15.31 - 15.65
Day's Volume 3,117
52-Week Range 12.85 - 21.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company'') (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneerin...

1 week ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...

2 weeks ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company'), a late-stage clinical biotechnology company pioneeri...

1 month ago - Business Wire

Nanobiotix (NASDAQ: NBTX) and PharmaEngine Inc have agreed to terminate the license and collaboration agreement announced in August 2012. The agreement provided PharmaEngine exclusive rights to further ...

1 month ago - Benzinga

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based approaches to ...

1 month ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering p...

1 month ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #NBTXR3--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based appr...

1 month ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #cancer--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based appro...

1 month ago - Business Wire

NBTXR3 has shown significant ability to improve effectiveness of radiotherapy in clinical studies. Approximately 60% of all cancer patients receive some for of radiotherapy.

2 months ago - Seeking Alpha

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #NBTXR3--Regulatory News: “We believe that NBTXR3 could have a positive impact for patients with cancer in any case where radiotherapy is a part of the standa...

2 months ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #NBTX--NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing f...

2 months ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing first-in-class prod...

2 months ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company”), a clinical-stage biotechnology company focused on developing first-in-c...

3 months ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing first-in-class product ...

3 months ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to ...

4 months ago - Business Wire

PARIS--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to the treatme...

Other stocks mentioned: NNBXF
4 months ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approac...

Other stocks mentioned: NNBXF
4 months ago - Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approac...

Other stocks mentioned: NNBXF
4 months ago - Business Wire

About NBTX

Nanobiotix is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use our proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. Our lead product candidate, NBTXR3, is an aqueous suspension of functionalized crystalline hafnium oxide nanoparticles designed for injection directly into a malignant tumor prior to standard radiotherapy. When exposed to ionizing radiation, NBTXR3 amplifies the localized, intratumor killing effect of that radiation and may a... [Read more...]

Industry
Biotechnology
IPO Date
Dec 11, 2020
CEO
Laurent Levy
Employees
88
Stock Exchange
NASDAQ
Ticker Symbol
NBTX
Full Company Profile

Financial Performance

In 2020, Nanobiotix's revenue was 2.51 million, a decrease of -1.14% compared to the previous year's 2.54 million. Losses were -33.59 million, -34.03% less than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Nanobiotix is 24.80, which is an increase of 58.47% from the latest price.

Price Target
$24.80
(58.47% upside)